Key facts
- It has raised $18.6M; the latest was Later Stage VC in Dec 2024.
- Notable investors include Co-Win Ventures, Beijing Delian Yuntong Investment Management Company, Kunnuo Tianqin Venture Capital, Shanghai Guofang Fund of Funds Equity Investment Management, Zhejiang Huarui Holdings.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for D1 Medical Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for D1 Medical Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About D1 Medical Technology
Developer and manufacturer of organoid technology intended to support regeneration medicine and transplantation. The company develops organoids to improve the development of disease diagnosis and treatment, new drug screening, and tumor marker identification, providing accurate, efficient and high-quality organoid models for new drug development and personalized treatments.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2019
- Website
- d1med.com/
- Ownership
- Privately Held (backing)
D1 Medical Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in D1 Medical Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on D1 Medical Technology in its N-PORT filings yet. We sweep new filings monthly.